BioCardia Announces FDA Market Clearance of Morph® DNA(TM) Steerable Introducer Product Family

Stock Information for BioCardia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioCardia Inc.

BioCardia Regains Full Compliance with Nasdaq Listing Requirements
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
BioCardia Submits for FDA Approval of Morph® DNA(TM) Steerable Introducer Product Family
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.